Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Public-Private Partnership Roundup

Highlights of public-private partnerships from 3Q15

PPP activity was down slightly in 3Q15 compared with the previous quarter, with 61 partnerships announced during that span. Big pharmas and biotechs continue to pair up with public and academic institutions at a high rate, taking part in 13 of the third quarter deals. Of those 13 partnerships, GlaxoSmithKline plc and AstraZeneca plc were each involved in four, including one that involved both pharmas. (See "Drug Connection." BioCentury Innovations (Aug. 20, 2015))

WuXi NextCODE's Chinese move

As precision medicine gathers steam in the U.S. and Europe through private and public initiatives, Chinese genomics company WuXi NextCODE is launching its pediatric diagnostics activities in China with a partnership with the Children's Hospital of Fudan University (CHFU) that will give it access to over 900,000 patients a year.

The company, a subsidiary of WuXi PharmaTech Inc., was formed in January following the acquisition of NextCODE, a spinout of deCode genetics Inc., to merge the whole genome and

Read the full 1533 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE